- Home
- ALXO vs BTMD Comparison
ALXO vs BTMD Comparison
Compare ALXO & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALXO | BTMD |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.7M | 80.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALXO | BTMD |
|---|---|---|
| Price | $1.33 | $2.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $3.30 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 177.3K | 116.0K |
| Earning Date | 11-07-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 270.48 |
| EPS | N/A | ★ 0.78 |
| Revenue | N/A | ★ $195,645,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.80 |
| P/E Ratio | ★ N/A | $3.56 |
| Revenue Growth | N/A | ★ 1.34 |
| 52 Week Low | $0.40 | $2.32 |
| 52 Week High | $2.27 | $6.36 |
Technical Indicators
Market Signals| Indicator | ALXO | BTMD |
|---|---|---|
| Relative Strength Index (RSI) | 42.54 | 49.71 |
| Support Level | $1.37 | $2.56 |
| Resistance Level | $1.53 | $2.80 |
| Average True Range (ATR) | 0.11 | 0.14 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 12.12 | 37.14 |
Price Performance
Historical ComparisonAbout ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.